am -
pm ET

Frequently Asked Questions (FAQs)

What is Alnylam Assist™?

Alnylam Assist™ includes Case Managers, Patient Education Liaisons, and Field Reimbursement Directors who provide support to patients prescribed Alnylam therapies. This support includes: verification of insurance benefits, coverage and reimbursement education, financial assistance support for eligible patients, and disease and product education. Each member of our team is assigned to specific geographic regions to work with patients, their caregivers, healthcare providers, and insurance companies to support patients throughout treatment on AMVUTTRA® (vutrisiran). See how Alnylam Assist™ can support you throughout treatment ›

How do I get started in the Alnylam Assist™ program?

In order to enroll in the program, you must be prescribed AMVUTTRA and fill out the Start Form with your doctor. Once the form is completed and you've signed it, your doctor can submit the form online or print it out and fax it to Alnylam Assist™. Find out more about getting started ›

What support services does Alnylam Assist™ provide?

Alnylam Assist™ focuses on 3 key areas of support services for patients and their families: insurance benefit verification, financial assistance options for eligible patients, and disease and product education. Find out more about the support services offered ›

Who are Case Managers?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing product support. They will tailor their method of communication to what works best for you.

An Alnylam Case Manager can help you understand your insurance coverage and options for financial support based on eligibility, as well as provide you with educational resources. Learn how you can work together with your own personal Case Manager ›

Who are Patient Education Liaisons (PELs)?

PELs have a background in nursing and are experienced in educating individuals and their families about matters related to hereditary ATTR (hATTR) amyloidosis. PELs can help you in a variety of ways, including providing disease and product education, connecting you to additional resources, and answering questions about treatment. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. Learn about the PEL team and how to get connected ›

What additional resources are available?

In addition to the personalized services that are part of Alnylam Assist™, there are also educational and support resources for patients and their families. These include downloadable materials about the polyneuropathy of hATTR amyloidosis and treatment with AMVUTTRA, as well as links to advocacy groups that connect patients to the hATTR amyloidosis community. Find out what’s available to support you and your family ›

What if I'm a caregiver?

Alnylam Assist™ is here to support you by helping your loved one access AMVUTTRA® and providing you education about the polyneuropathy of hATTR amyloidosis. We can also connect you to independent organizations that can offer additional resources ›

How can I contact Alnylam Assist™?

A Case Manager from Alnylam Assist™ is available from 8am - 6pm, Monday - Friday at 1-833-256-2748.

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with AMVUTTRA, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Natalie

Call Natalie


Monday - Friday, 8am - 6pm

Alylam Separator Triangles


What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause:

Low Vitamin A Levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


What is AMVUTTRA® (vutrisiran)?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin‑mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.